Department of Otolaryngology-Head and Neck Surgery, Chinese PLA General Hospital, Beijing, China.
Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Eur Radiol. 2024 Jan;34(1):569-578. doi: 10.1007/s00330-023-09908-2. Epub 2023 Aug 7.
Microwave ablation (MWA) has emerged as a minimally invasive technology for papillary thyroid microcarcinoma (PTMC), but it has not been widely applied to treat T1bN0M0 PTC with high-level evidence. This study was designed to compare the real-world efficacy and safety of MWA or surgery for treating T1bN0M0 PTC.
From December 2019 to April 2021, 123 continuous unifocal T1bN0M0 PTC patients without lymph node metastasis (LNM) or distant metastasis (DM) were included from 10 hospitals. Patients were allocated into the MWA or surgery group based on their willingness. The main outcomes were local tumour progression (LTP), new thyroid cancer, LNM, and DM. The secondary outcomes included changes in tumour size and volume, complications, and cosmetic results. Subgroup analyses were conducted to identify influencing factors.
Fifty-two patients chose MWA, and 71 patients chose surgery. Patients had similar demographic information and tumour characteristics in the two groups. The follow-up durations after MWA and surgery were 10.6 ± 4.2 and 10.4 ± 3.4 months, respectively. The LNM rate was 5.8% in the MWA group and 1.4% in the surgery group (p = 0.177). No LTP, new thyroid cancer, or distant metastasis (DM) occurred in either group. Five (9.6%) of the 52 patients in the MWA group and 8 (11.3%) of the 71 patients in the surgery group had complications (p = 0.27). Better cosmetic results were found in the MWA group (p < 0.01).
MWA achieved comparable short-term treatment efficacy with surgery. MWA might be an optional choice for surgery for low-risk T1bN0M0 PTC but concerns about LNM need to be studied further.
MWA achieved comparable short-time treatment efficacy with surgery. MWA might be an optional choice for surgery for low-risk T1bN0M0 PTC.
• MWA achieved comparable short-term treatment efficacy with surgery. MWA might be an optional choice for surgery for low-risk T1bN0M0 PTC but concerns about LNM need to be studied further. • The complication rate in the surgery group was higher than that in the MWA group without a significant difference. • There was no statistically significant difference in the LNM rate between the MWA and surgery groups.
微波消融(MWA)已成为治疗甲状腺微小乳头状癌(PTMC)的一种微创技术,但尚无高水平证据支持其用于治疗 T1bN0M0 型甲状腺癌。本研究旨在比较 MWA 与手术治疗 T1bN0M0 型甲状腺癌的真实疗效和安全性。
本研究纳入了 2019 年 12 月至 2021 年 4 月间来自 10 家医院的 123 例连续单发 T1bN0M0 型无淋巴结转移(LNM)或远处转移(DM)的甲状腺微小乳头状癌患者。根据患者意愿将其分为 MWA 组或手术组。主要结局为局部肿瘤进展(LTP)、新发甲状腺癌、LNM 和 DM。次要结局包括肿瘤大小和体积的变化、并发症和美容效果。进行了亚组分析以确定影响因素。
52 例患者选择 MWA,71 例患者选择手术。两组患者的人口统计学信息和肿瘤特征相似。MWA 组和手术组的随访时间分别为 10.6±4.2 个月和 10.4±3.4 个月。MWA 组的 LNM 率为 5.8%,手术组为 1.4%(p=0.177)。两组均未发生 LTP、新发甲状腺癌或 DM。MWA 组有 5(9.6%)例患者和手术组有 8(11.3%)例患者发生并发症(p=0.27)。MWA 组的美容效果更好(p<0.01)。
MWA 与手术治疗具有相当的短期疗效。MWA 可能是低危 T1bN0M0 型甲状腺癌的手术可选方案,但需要进一步研究 LNM 相关问题。
MWA 与手术治疗具有相当的短期疗效。MWA 可能是低危 T1bN0M0 型甲状腺癌的手术可选方案。
MWA 与手术治疗具有相当的短期疗效。MWA 可能是低危 T1bN0M0 型甲状腺癌的手术可选方案,但需要进一步研究 LNM 相关问题。
手术组的并发症发生率高于 MWA 组,但差异无统计学意义。
MWA 组与手术组的 LNM 率无统计学差异。